

Integra LifeSciences Features New LED Headlight System at American College of Surgeons Congress

PLAINSBORO, N.J., Oct. 24, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp (Nasdaq:IART) today announced the launch of its new Integra[™] LED Headlight System, a surgical headlight system that is designed to deliver the cool brightness and color surgeons need for visibility, along with increased mobility in the operating room. The LED Headlight System has received 510(k) clearance from the United States Food and Drug Administration (FDA), and will be featured at the 2011 American College of Surgeons 97th Annual Clinical Congress in San Francisco, California, October 23-27, 2011.

The new IntegraTM LED Headlight System's vibrant color rendition maximizes visualization of critical anatomy across a broad range of surgical procedures. Its 25,000+ hour lamp life helps limit uncertainty by ensuring a dramatically longer life than more traditional xenon surgical lighting systems, which have a lamp life of approximately 1,000 hours. The LED Headlight System also provides greater mobility with either a lightweight 20-foot power cord that eliminates the clutter of floor stands and fiber optic cables, or a light weight battery option that allows surgeons untethered mobility within the operating room.

"We expect surgeons will welcome the same low cost of ownership, cool output and extremely long life that's helping LEDs become the standard in other markets. In addition, this self-contained headlight doesn't require fiber optic cords, introducing surgeons to a new level of independence, by allowing them to move more freely about the operating room," said Dan Reuvers, President, Instruments.

Integra currently offers an extensive range of surgical illumination products and accessories, including the IntegraTM Luxtec[®] MLX 300W Xenon system, IntegraTM Luxtec[®] 9300 XSP 300W Xenon system, IntegraTM ProXenon[®] 300W Xenon system, as well as IntegraTM UltraLite[®] Pro and CoolVentTM headlight systems.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit <u>www.integralife.com</u>

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella Director, Corporate Communications (609) 936-2389 gianna.sabella@integralife.com